Craft

Blueprint Medicines

Stock Price

$106.1

2024-06-12

Market Capitalization

$6.6 B

2024-06-12

Revenue

$249.4 M

FY, 2023

Blueprint Medicines Summary

Company Summary

Overview
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders. Its research technology combines bioinformatics, structural and cell biology, and a proprietary library of novel compounds. The company aims to help patients with genomically defined cancers, rare diseases, and cancer immunotherapy.
Type
Public
Status
Active
Founded
2011
HQ
Cambridge, MA, US | view all locations
Website
https://www.blueprintmedicines.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Jeffrey Albers

    Jeffrey Albers, Executive Chairman of the Board of Directors

  • Andrew Law

    Andrew Law, Director, Corporate Communications

  • Percy Carter, Chief Scientific Officer

    • Kate Haviland

    LocationsView all

    4 locations detected

    • Cambridge, MA HQ

      United States

      45 Sidney St

    • Amsterdam, NH

      Netherlands

      Gustav Mahlerplein 2

    • Lugano, TI

      Switzerland

      Via Emilio Bossi 6

    • Zug, ZG

      Switzerland

      Baarerstrasse 8

    Blueprint Medicines Financials

    Summary Financials

    Revenue (Q1, 2024)
    $96.1M
    Gross profit (Q1, 2024)
    $92.9M
    Net income (Q1, 2024)
    $89.1M
    Cash (Q1, 2024)
    $113.3M
    Enterprise value
    $6.8B

    Footer menu